Answers are grounded in this paper and cite their sources.
The p53 signaling pathway is a key regulator of genomic stability and cellular stress responses. Beyond TP53 mutations, p53 dysfunction in malignant primary central nervous system (CNS) tumors results from multiple genetic and epigenetic alterations, contributing to tumor initiation, progression, therapeutic resistance, and interactions with the tumor microenvironment. Recent advances have transformed p53 from a classical tumor suppressor into an attractive therapeutic target. This review summarizes the current understanding of the molecular biology of the p53 pathway in malignant primary CNS tumors and discusses emerging therapeutic strategies aimed at restoring or exploiting p53 signaling. Current evidence from experimental, translational, and clinical studies was critically reviewed, with particular emphasis on IDH-wildtype glioblastoma, IDH-mutant astrocytoma, pediatric-type diffuse high-grade gliomas, medulloblastoma, and other malignant CNS tumors. The molecular mechanisms of p53 pathway dysregulation and recent advances in p53-targeted therapies were analyzed. Accumulating evidence demonstrates that p53 pathway dysregulation extends beyond TP53 mutations and involves aberrant MDM2/MDM4 activity, altered stress-response signaling, mutant p53 gain-of-function, and epigenetic mechanisms. Therapeutic approaches targeting these alterations—including MDM2/MDM4 inhibitors, mutant p53 reactivators, direct p53-targeting compounds, gene- and RNA-based therapies, and rational combination strategies—have shown encouraging preclinical and early clinical activity. However, tumor heterogeneity, blood–brain barrier penetration, adaptive resistance, and the need for biomarker-guided patient selection remain major obstacles to successful clinical translation. The p53 pathway represents a potential therapeutic target in neuro-oncology, although the clinical efficacy of p53-directed approaches in primary CNS tumors remains unestablished. Further studies are required to determine whether molecularly guided strategies can translate into meaningful clinical benefit.
No takes yet. Share an insight, caveat, or question.
Rangno et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: